Literature DB >> 20367799

Effect of otilonium bromide on contractile patterns in the human sigmoid colon.

D Gallego1, M Aulí, J Aleu, E Martínez, L Rofes, J Martí-Ragué, M Jiménez, P Clavé.   

Abstract

BACKGROUND: The mechanism of action of the spasmolytic compound otilonium bromide (OB) on human colonic motility is not understood. The aim of our study was to characterize the pharmacological effects of OB on contractile patterns in the human sigmoid colon.
METHODS: Circular sigmoid strips were studied in organ baths. Isolated smooth muscle cells from human sigmoid colon were examined using the calcium imaging technique. KEY
RESULTS: Otilonium bromide inhibited by 85% spontaneous non-neural rhythmic phasic contractions (RPCs), (IC(50) = 49.9 nmol L(-1)) and stretch-induced tone (IC(50) = 10.7 nmol L(-1)) with maximum effects at micromolar range. OB also inhibited by 50% both on- (IC(50) = 38.0 nmol L(-1)) and off-contractions induced by electrical stimulation of excitatory motor neurons. In contrast, the inhibitory latency period prior to off-contractions was unaffected by OB. OB inhibited acetylcholine-, substance P-, and neurokinin A-induced contractions. The L-type Ca(2+) channel agonist BayK8644 reversed the effects of OB on RPCs, on- and off-contractions. Hexamethonium, atropine, the NK(2) antagonist, or depletion of intracellular Ca(2+) stores by thapsigargin did not prevent the inhibitory effect of OB on RPCs and electrical contractions. KCl-induced calcium transients in isolated smooth muscle cells were also inhibited by OB (IC(50) = 0.2 micromol L(-1)). CONCLUSIONS & INFERENCES: Otilonium bromide strongly inhibited the main patterns of human sigmoid motility in vitro by blocking calcium influx through L-type calcium channels on smooth muscle cells. This pharmacological profile may mediate the clinically observed effects of the drug in patients with irritable bowel syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367799     DOI: 10.1111/j.1365-2982.2010.01495.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  10 in total

1.  In vitro motor patterns and electrophysiological changes in patients with colonic diverticular disease.

Authors:  Diana Gallego; Francisco Espín; Jan Mikulka; Ondřej Šmirg; Víctor Gil; Marcos Faundez-Zanuy; Marcel Jiménez; Pere Clavé
Journal:  Int J Colorectal Dis       Date:  2013-05-24       Impact factor: 2.571

2.  Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.

Authors:  G Cipriani; S J Gibbons; S A Saravanaperumal; J Malysz; L Sha; J H Szurszewski; D R Linden; S Evangelista; M S Faussone-Pellegrini; M G Vannucchi; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2015-04-30       Impact factor: 3.598

Review 3.  Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.

Authors:  Jakub Rychter; Francisco Espín; Diana Gallego; Patri Vergara; Marcel Jiménez; Pere Clavé
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

Review 4.  New and Investigational Agents for Irritable Bowel Syndrome.

Authors:  Akhilesh Wadhwa; Michael Camilleri; Madhusudan Grover
Journal:  Curr Gastroenterol Rep       Date:  2015-12

Review 5.  IBS and the role of otilonium bromide.

Authors:  Guy Boeckxstaens; Enrico S Corazziari; Fermín Mearin; Jan Tack
Journal:  Int J Colorectal Dis       Date:  2012-11-22       Impact factor: 2.571

6.  Inner and outer portions of colonic circular muscle: ultrastructural and immunohistochemical changes in rat chronically treated with otilonium bromide.

Authors:  Chiara Traini; Maria Simonetta Faussone-Pellegrini; Stefano Evangelista; Katia Mazzaferro; Gianluca Cipriani; Paolo Santicioli; Maria Giuliana Vannucchi
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

7.  Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis.

Authors:  Pere Clavé; Jan Tack
Journal:  Therap Adv Gastroenterol       Date:  2017-01-16       Impact factor: 4.409

Review 8.  Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review.

Authors:  John K Triantafillidis; George Malgarinos
Journal:  Clin Exp Gastroenterol       Date:  2014-04-07

9.  Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium.

Authors:  Kang Nyeong Lee; Oh Young Lee; Myung-Gyu Choi; Chong Il Sohn; Kyu Chan Huh; Kyung Sik Park; Joong Goo Kwon; Nayoung Kim; Poong-Lyul Rhee; Seung-Jae Myung; Joon Seong Lee; Kwang Jae Lee; Hyojin Park; Yong Chan Lee; Suck Chei Choi; Hye-Kyung Jung; Sam Ryong Jee; Chang Hwan Choi; Gwang Ha Kim; Moo In Park; In Kyung Sung
Journal:  J Neurogastroenterol Motil       Date:  2013-12-30       Impact factor: 4.924

10.  Effect of Samryungbaekchul-san Combined with Otilonium Bromide on Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Randomized Controlled Trial.

Authors:  Jin-Hyun Lee; Joong Il Kim; Myong Ki Baeg; Yun-Young Sunwoo; Kwangsun Do; Jung-Han Lee; Hye-Jung Kim; Ja Sung Choi; Jayoung Kim; Chang-Seob Seo; Hyeun-Kyoo Shin; Hyekyung Ha; Tae-Yong Park
Journal:  J Clin Med       Date:  2019-09-27       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.